Close

Allos recruits first patient in Phase 3 PTCL drug trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Allos Therapeutics has recruited first patient in a Phase 3 multi-center, randomized, open-label (PDX-017) Phase 2 trial investigating Folotyn (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). Folotyn is approved in the US as a treatment for the patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).The study aims to determine the efficacy and safety of equential Folotyn versus observation in patients with previously undiagnosed PTCL who have achieved an objective response following initial treatment with CHOP or a CHOP-like regimen.

Currently, the study is open to recruit newly diagnosed PTCL patients who have achieved an objective response following initial treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen.

Latest stories

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back